Sandgaard Capital

12/17/2025

In Sandgaard Capital's latest Executive Insight, we break down how macroeconomic conditions, sector fundamentals, and shifting capital flows are shaping risk and opportunity in today’s real estate landscape.

Whether you are evaluating residential, commercial, or alternative real estate strategies, this analysis provides a data-driven framework for decision-making as we close out 2025.

Read the full article here to learn more: https://www.sandgaardcapital.com/executiveinsights/executive-insight-the-current-state-of-real-estate-investments

09/18/2025

Thomas Sandgaard, CEO of Sandgaard Capital, shares his perspective on the state of the economy in 2025 — where resilience meets uncertainty, and opportunity emerges.

Read his full insights here: https://www.sandgaardcapital.com/executiveinsights/the-state-of-the-economy-perspective-from-sandgaard-capital

By: Thomas Sandgaard, CEO of Sandgaard Capital

08/18/2025

📢 Leadership Update at Zynex Inc (NASDAQ: ZYXI)

We’re excited to share that Steven Dyson has officially taken the helm as CEO of Zynex, joined by a strengthened executive team:

- Vikram Bajaj – Chief Financial Officer (finance & strategy leader with 20+ years in medtech)

- John T. Bibb – Chief Legal Officer (legal, HR & compliance expertise across major healthcare firms)

- Ajay Gopal – EVP of Sales (track record of commercial growth and expanding patient access)

- Agnes Powell – VP of Billing (20 years of experience in revenue cycle and managed care operations)

Board Chairman Thomas Sandgaard expressed confidence in this proven group of leaders to “take Zynex to new levels of success.”

CEO Steven Dyson added: “We have the right team in place to deliver excellent results while renewing our commitment to integrity and improving quality of life for patients suffering from pain and illness.”

📈 Zynex shares rose nearly 6% following the announcement.

At Sandgaard Capital, we remain committed to supporting Zynex as it enters this next phase of growth and transformation.

Click here to learn more: https://www.proactiveinvestors.com/companies/news/1076873/zynex-beefs-up-executive-team-as-new-ceo-dyson-takes-helm-1076873.html

$ZYXI

07/08/2025

Zynex Medical and Zynex Monitoring Solutions (Nasdaq: ZYXI) appoints Steven Dyson as CEO; founder Thomas Sandgaard transitions to the Chairman role to steer the vision.

Zynex Inc. announced a significant leadership transition as Founder and longtime CEO Thomas Sandgaard steps into the role of Chairman of the Board and Chair of the Technology Committee, while Steven Dyson assumes the position of Chief Executive Officer.

In a joint conversation with Steve Darling from Proactive, Sandgaard explained that this move marks a strategic evolution for Zynex as it adapts to a dynamic healthcare environment. Sandgaard, who founded the company in 1996 and led it from inception to Nasdaq listing, emphasized that Dyson brings the leadership, experience, and global perspective necessary to take Zynex to the next level.

Steven Dyson joins Zynex with more than 25 years of international leadership experience in the medical technology and healthcare sectors. Most notably, Dyson served as a senior executive at Apax Partners, a leading private equity firm (~$80Bn AUM) where he played key roles in scaling and exiting high-profile healthcare companies across Europe, North America, and Asia. His track record includes transformative roles at KCI, Rodenstock, Unilabs, Healthium Medtech, and Neuraxpharm, giving him a robust foundation in growth strategy, operational optimization, and global expansion.

At Zynex, Dyson will lead the company through a refined strategic focus, particularly targeting a more optimized payer mix, streamlined operations, and expanded market pe*******on in non-invasive pain management and medical diagnostic devices.

As Chairman, Sandgaard will continue to shape Zynex’s product and technology pipeline, ensuring its R&D efforts remain competitive and aligned with evolving healthcare trends, especially in pain relief solutions and wearable diagnostics.

This leadership evolution underscores Zynex’s commitment to growth, modernization, and value creation, with a steady hand at the helm and a fresh operational engine poised to accelerate the company’s trajectory in the medtech space.

Watch the full interview here: https://www.proactiveinvestors.com/companies/news/1074351/zynex-appoints-steven-dyson-as-ceo-founder-thomas-sandgaard-moves-to-chairman-role-to-steer-vision.html

06/25/2025

🚨 Zynex (NASDAQ: ZYXI) Secures UK Patent for Non-Invasive Sepsis Monitoring Technology 🚨

Zynex Monitoring Solutions has been awarded a UK patent for its groundbreaking multiparameter, non-invasive sepsis monitor — a device designed to help clinicians detect sepsis earlier by continuously tracking multiple vital signs.

🦠 Sepsis affects over 1.7 million people annually in the U.S. and is responsible for 1 in 3 hospital deaths.

📊 Early detection remains one of the biggest challenges in treating this life-threatening condition.

🌍 Zynex’s technology supports global efforts like the Surviving Sepsis Campaign to reduce sepsis-related mortality.

CEO Thomas Sandgaard stated:
“Sepsis is a global health crisis. This technology has the potential to drastically reduce deaths by delivering real-time, non-invasive data to clinicians.”

Donald Gregg, President of Zynex Monitoring Solutions, added:
“We believe we can significantly contribute to earlier detection and better outcomes.”

Zynex continues to lead innovation in critical care monitoring with a focus on improving patient lives.

Read more here: https://www.proactiveinvestors.com/companies/news/1073616/zynex-awarded-uk-patent-for-non-invasive-sepsis-monitoring-technology-1073616.html

06/24/2025

Big News: Zynex Medical and Melling Medical Are Expanding Access to Non-Invasive Pain Relief for Veterans and Military Personnel! 💥

Two leaders in healthcare have joined forces to bring innovative, non-pharmacological pain management solutions to the entire federal healthcare system. 🙌

What’s happening:
🤝 Zynex Medical is partnering with MellingMedical, a Service-Disabled Veteran-Owned Small Business (SDVOSB)

📦 Zynex’s breakthrough devices, like the NexWave (combining IFC, TENS, NMES) will now be available to:
- 172 VA Medical Centers
- 1,138 VA Outpatient Clinics
- 95 DoD Medical Facilities

7 VA Consolidated Mail Outpatient Pharmacies (CMOPs)
- Why it matters:
- Offers non-invasive alternatives to opioids
- Helps reduce dependency on pain meds while improving outcomes
- Includes electrotherapy devices, bracing solutions, and rehab tools for chronic pain and functional disabilities
- “This is about delivering innovation where it’s needed most—serving those who’ve served our country,” said Zynex Founder & CEO, Thomas Sandgaard.

👏 A huge step forward in federal pain care, and a powerful reminder that healing doesn’t have to come in a pill bottle.

05/21/2025

🚨 Major update from Zynex Monitoring Solutions (NASDAQ: ZYXI): The company has officially submitted its NiCO™ non-invasive CO-Oximeter to the FDA for clearance.

💡 Why this matters:
NiCO™ is a breakthrough medical device designed to address long-standing flaws in traditional pulse oximeters. It uses proprietary laser technology—rather than outdated LEDs—to provide accurate oxygen readings across all skin tones, even with nail polish. Critically, it also detects carbon monoxide poisoning non-invasively and instantly, a capability that existing devices lack.

🗣️ CEO Thomas Sandgaard explained:
“This device can make a very significant and very meaningful difference... It provides instant information, even in cases of carbon monoxide poisoning, and reads accurately regardless of dark skin or even nail polish.”

🩺 Traditional pulse oximeters have seen little innovation in decades and have shown major blind spots—especially for patients with darker skin, as highlighted during the COVID-19 pandemic. NiCO™ aims to solve that, offering hospitals and clinicians more reliable, equitable data.

🎯 The initial target market is hospitals—part of a $1B+ global opportunity—but the broader implications for patient care and health equity are even more far-reaching.

🗓️ Zynex expects a response from the FDA in approximately 6 months and is preparing for commercial launch shortly thereafter.

🔗 Read the full article via Proactive Investors: https://www.proactiveinvestors.com/companies/news/1071653/zynex-submits-fda-application-for-nico-a-breakthrough-non-invasive-co-oximeter.html

05/13/2025

Big News from Zynex Monitoring Solutions!

Zynex has officially submitted its FDA 510(k) application for the NiCO™ laser-based pulse oximeter — a next-gen innovation that could redefine accuracy in oxygen monitoring.

🔬 Unlike traditional red-infrared tech, NiCO™ uses laser light to potentially detect oxygen saturation and pulse rate more reliably — especially in patients with poor circulation, dark skin pigmentation, or low perfusion.

Why does this matter?
➡️ Lives depend on precision.
➡️ Millions of patients are monitored daily with oximeters.
➡️ Greater accuracy = better outcomes in critical care, surgery, and recovery.

This marks a bold step forward in Zynex’s commitment to patient-first innovation. 🚀 Zynex is not just treating pain — they are pushing boundaries in non-invasive monitoring.

📈 Stay tuned as we await feedback from the FDA. If cleared, NiCO™ could become a game-changer in clinical settings across the country.

Click the following link to learn more: https://www.proactiveinvestors.co.uk/companies/news/1071056/zynex-submits-fda-application-for-nico-laser-pulse-oximeter-1071056.html

Zynex Inc (NASDAQ:ZYXI) announced it has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its NiCO Noninvasive CO-Oximeter...

04/25/2025

🏆 Danish Champions! A Historic Moment for the Odense Bulldogs!🏆

Today, Sandgaard Capital's Odense Bulldogs reached the pinnacle of Danish professional hockey and are now Danish Champions!

"We are honored to own and invest in this remarkable professional hockey team as they etch their names into history. This victory is a milestone that will inspire future generations of Bulldogs — and it’s only the beginning of even greater things to come." - Thomas Sandgaard 🏒

"Congratulations to the entire organization, the fans, and the city of Odense! Let’s savor this moment — Champions of Denmark!" - Martin Sandgaard

"Winning the national championship isn’t just about lifting a trophy — it’s a testament to the years of hard work, resilience, and belief that define this incredible team. It represents the heart of Odense, the spirit of competition, and the pride of an entire community." - Kyle D. Henderson

04/08/2025

💥 Fighting pain without pills! 💪

Zynex Medical’s Stephen Fox shares how their flagship device, NexWave, is changing the game in pain management ✨

✅ Noninvasive
✅ Non-addictive
✅ At-home relief

With three (3) powerful therapies (TENS, IFC, NMES), NexWave helps patients recover safely without side effects — no opioids needed. 🙅‍♂️💊

📢 Nearly 300 reps across the U.S. are educating providers and pushing back against the opioid crisis.

“We’re united by one mission: better, safer pain relief,” says Fox 💙

Watch the interview and read the article here to learn more: https://www.proactiveinvestors.com/companies/news/1069097/zynex-medical-champions-noninvasive-non-addictive-pain-management-with-nexwave.html

02/28/2025

💙 Zynex Medical (Nasdaq: ZYXI) Leads the Way in Non-Opioid Pain Relief!

📢 Zynex COO Anna Lucsok shares how Zynex is making pain management accessible with:

✅ Strong insurance coverage across thousands of providers 🏥
✅ Cutting-edge medical devices like electrotherapy & bracing ⚡🦾
✅ Explosive growth—sales productivity doubled in 2 years 📈🔥
✅ Big plans ahead—expanding sales force & launching new innovations 🚀

Zynex is on a mission to make medication-free pain relief the new standard! 💡💪

Read the entire article here to learn more: https://www.proactiveinvestors.com/companies/news/1067178/zynex-coo-on-pain-management-innovations-and-growth-plans-icymi-1067178.html

01/28/2025

Zynex Expands Medical Innovation Portfolio! ✨

Zynex Inc. (Nasdaq: ZYXI) is breaking barriers with its cutting-edge NiCO laser pulse oximeter, designed for unparalleled precision in measuring blood oxygen levels.

Following successful trials at Duke University, the device addresses inaccuracies in traditional oximeters, particularly for individuals with darker skin tones, paving the way for equitable healthcare solutions.

The company eyes FDA submission by June and continues its mission to revolutionize pain management with products like the NexWave and TensWave devices.

✨Big news: Zynex recently partnered with Veterans Affairs Medical Centers, opening doors to serve over 9 million veterans with advanced, non-opioid pain management solutions.

Stay tuned for updates as Zynex shapes the future of healthcare!

Read the entire article via the following link to learn more: https://www.proactiveinvestors.com/companies/news/1065206/zynex-eyes-fda-submission-for-nico-oximeter-as-it-expands-portfolio-of-innovative-medical-devices-1065206.html

Zynex Medical Zynex Monitoring Solutions Thomas Sandgaard |

Zynex Inc (NASDAQ:ZYXI) continues to expand its portfolio of innovative, non-invasive medical devices targeting pain management, rehabilitation, and pain...